Product Overview
This combination pairs CJC-1295 (a modified GHRH analog with extended half-life) with Ipamorelin (a selective GHS receptor agonist that does not elevate cortisol or prolactin). The "pulse and sustain" approach — Ipamorelin providing an immediate strong GH dump, CJC-1295 extending elevated levels — more closely mimics the body's natural hormone secretion patterns than either peptide alone. This amplifies endogenous GH production rather than introducing synthetic hormones.
Mechanism of Action
CJC-1295 binds to GHRH receptors for sustained pituitary GH stimulation over an extended period. Ipamorelin acts directly on ghrelin/GHS receptors for an immediate, strong GH pulse. Together, they optimize both availability and intensity of GH release while maintaining natural feedback regulation. The combined GH elevation increases IGF-1 production, supporting muscle, metabolism, and cellular health.
Key Benefits
Amplified GH Production — Synergistic effect produces more powerful results than either peptide alone. Increases circulating growth hormone for comprehensive physiological benefits.
Muscle Growth & Fat Loss — Enhanced protein synthesis, cellular replication, and collagen synthesis support muscle development. Decreased fat accumulation through improved IGF-1-mediated fat metabolism.
Recovery & Sleep — Deeper, more restorative sleep enhances cellular repair processes. Faster recovery from workouts and physical demands with more energy for daily activities.
Anti-Aging & Skin Health — Supports cellular regeneration, skin elasticity, hair and nail quality, and overall vitality by maintaining youthful GH levels.
References
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295. *J Clin Endocrinol Metab.* 2006;91(12):4792–4797.
- Morrison M, et al. Sleep, circadian biology and skeletal muscle interactions: implications for metabolic health. *Sleep Med Rev.* 2022;66:101700.
- Harvard Medical School. Preserve your muscle mass. *Harvard Health Publishing.* 2016.